Publication

Cost-effectiveness of Haemophilus influenzae type b vaccines for infants in mainland China

Authored by:

Ning G, Yin Z, Li Y et al

Full Citation:

Ning G, Yin Z, Li Y et al 2018. Cost-effectiveness of Haemophilus influenzae type b vaccines for infants in mainland China. Human Vaccines & Immunotherpeutics. 14.

View Publication

Additional key concepts from this publication:

Use of vaccines, including strengthening existing immunization programs, provides opportunities for significant reductions in disease burden with resultant economic benefits.

Key Evidence: If China — one of the few remaining countries in the world that haven’t introduced Hib vaccine in their national immunization program — decides to include the vaccine in their program, it could actually be cost saving; the vaccination costs would be less than the averted costs of illness from Hib meningitis and pneumonia, if a vaccine price matching UNICEF’s (US$2/dose) can be obtained. The vaccination will be cost-effective, but not cost saving, if the program pays the current market price in China of US$10 per dose.